Schear Investment Advisers LLC Raises Stock Position in Cencora, Inc. (NYSE:COR)

Schear Investment Advisers LLC lifted its position in Cencora, Inc. (NYSE:COR) by 2.5% in the fourth quarter, Holdings Channel reports. The firm owned 6,241 shares of the company’s stock after buying an additional 153 shares during the period. Schear Investment Advisers LLC’s holdings in Cencora were worth $1,402,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. Portfolio Design Labs LLC raised its position in Cencora by 76.9% during the 4th quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company’s stock valued at $2,479,000 after purchasing an additional 4,794 shares in the last quarter. Latitude Advisors LLC bought a new stake in shares of Cencora in the fourth quarter valued at about $559,000. Savant Capital LLC lifted its stake in Cencora by 4.1% in the fourth quarter. Savant Capital LLC now owns 7,312 shares of the company’s stock worth $1,643,000 after acquiring an additional 291 shares during the period. Harbour Trust & Investment Management Co increased its position in Cencora by 7.7% during the 4th quarter. Harbour Trust & Investment Management Co now owns 10,205 shares of the company’s stock valued at $2,293,000 after purchasing an additional 727 shares during the period. Finally, WCM Investment Management LLC raised its holdings in shares of Cencora by 99.1% in the 4th quarter. WCM Investment Management LLC now owns 2,116 shares of the company’s stock valued at $476,000 after purchasing an additional 1,053 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $246.86 on Wednesday. The stock has a 50-day moving average of $238.86 and a two-hundred day moving average of $237.03. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. The stock has a market cap of $47.71 billion, a P/E ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts predict that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. Cencora’s payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Robert W. Baird upped their price objective on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,187 shares of company stock worth $17,790,912. 10.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.